TRAVERE THERAPEUTICS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
TRAVERE THERAPEUTICS, INC. (TVTX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $77.42 million as of 2015-09-30, per its 10-Q filed 2015-11-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2015-11-06
- 2015-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $77.42M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2015-09-30 | $77.42M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |